Significance of migrainous features in cluster headache: Divalproex responsiveness

Headache

Volumn 38, Issue 7, 1998, Pages 547-551

  Wheeler, Steve D ^a  

^a Neurologic Center of South Florida   (United States)

Author keywords

Cluster; Cluster headache; Divalproex; Divalproex sodium; Migraine; Migrainous; Migrainous disorder; Sodium valporate

Indexed keywords

VALPROATE SEMISODIUM;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLUSTER HEADACHE; DRUG RESPONSE; HUMAN; MALE; MIGRAINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION;

EID: 0031655732     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1998.3807547.x     Document Type: Article

References (17)

1. Nappi G, Micieli G, Cavallini A, Zanferrari C, Sandrini G, Manzoni GC. Accompanying symptoms of cluster attacks: their relevance to the diagnostic criteria. Cephalalgia. 1992;12:165-168.
2. Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia. 1989;9:195-198.
3. Diamond S, Freitag FG, Diamond ML, Urban GJ, Pepper BJ, Bhambhavani D. Open-label long-term use of divalproex sodium in headache. Headache Q. 1997;8:42-46.
4. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
5. D'Amico D, Centonze V, Grazzi L, Leone M, Ricchetti G, Bussone G. Coexistence of migraine and cluster headache: report of 10 cases and possible pathogenetic implications. Headache. 1997;37:21-25.
6. Solomon S, Karfunkel P, Guglielmo KM. Migraine-cluster headache syndrome. Headache. 1985;25:236-239.
7. Solomon S. Diagnosis of primary headache disorders. Validity of the International Headache Society criteria in clinical practice. Neurol Clin. 1997;15:15-26.
8. Montagna P, Lodi R, Cortelli P, et al. Phosphorus magnetic resonance spectroscopy in cluster headache. Neurology. 1997;48:113-118.
9. Kobari M, Meyer JS, Ichijo M, Kawamura J. Cortical and subcortical hyperperfusion during migraine and cluster headache measured by Xe CT-CBF. Neuroradiology. 1990;32:4-11.
10. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-187.
11. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117:427-434.
12. Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia. 1994;14:320-327.
13. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nature Med. 1995;1:658-660.
14. Diener HC, May A. New aspects of migraine pathophysiology: lessons learned from positron emission tomography. Curr Opin Neurol. 1996;9:199-201.
15. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
16. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103-108.
17. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997;17:93-100.